nodes	percent_of_prediction	percent_of_DWPC	metapath
Isoprenaline—ADRB2—prostate cancer	0.212	0.538	CbGaD
Isoprenaline—CYP1A1—prostate cancer	0.182	0.462	CbGaD
Isoprenaline—CYP1A1—Flutamide—prostate cancer	0.0824	0.468	CbGbCtD
Isoprenaline—CYP1A1—Estrone—prostate cancer	0.0596	0.338	CbGbCtD
Isoprenaline—CYP1A1—Estradiol—prostate cancer	0.0342	0.194	CbGbCtD
Isoprenaline—PIK3R2—renal system—prostate cancer	0.00636	0.0965	CbGeAlD
Isoprenaline—PIK3R3—prostate gland—prostate cancer	0.00633	0.096	CbGeAlD
Isoprenaline—PIK3R1—prostate gland—prostate cancer	0.00541	0.082	CbGeAlD
Isoprenaline—ADRB3—prostate gland—prostate cancer	0.00383	0.0581	CbGeAlD
Isoprenaline—ADRBK1—prostate gland—prostate cancer	0.00374	0.0568	CbGeAlD
Isoprenaline—MAPK1—prostate gland—prostate cancer	0.00369	0.0559	CbGeAlD
Isoprenaline—PIK3R1—urethra—prostate cancer	0.00362	0.0549	CbGeAlD
Isoprenaline—PIK3R3—testis—prostate cancer	0.00279	0.0423	CbGeAlD
Isoprenaline—PIK3R1—bone marrow—prostate cancer	0.00279	0.0423	CbGeAlD
Isoprenaline—MAPK1—epithelium—prostate cancer	0.00271	0.0411	CbGeAlD
Isoprenaline—ADRBK1—renal system—prostate cancer	0.00255	0.0387	CbGeAlD
Isoprenaline—MAPK1—renal system—prostate cancer	0.00251	0.0381	CbGeAlD
Isoprenaline—PIK3R1—testis—prostate cancer	0.00238	0.0361	CbGeAlD
Isoprenaline—PIK3R3—lymph node—prostate cancer	0.00202	0.0307	CbGeAlD
Isoprenaline—ADRBK1—bone marrow—prostate cancer	0.00193	0.0293	CbGeAlD
Isoprenaline—MAPK1—bone marrow—prostate cancer	0.0019	0.0288	CbGeAlD
Isoprenaline—PIK3R1—lymph node—prostate cancer	0.00173	0.0262	CbGeAlD
Isoprenaline—ADRBK1—testis—prostate cancer	0.00165	0.025	CbGeAlD
Isoprenaline—MAPK1—testis—prostate cancer	0.00162	0.0246	CbGeAlD
Isoprenaline—ADRB1—prostate gland—prostate cancer	0.00156	0.0237	CbGeAlD
Isoprenaline—ADRBK1—lymph node—prostate cancer	0.00119	0.0181	CbGeAlD
Isoprenaline—MAPK1—lymph node—prostate cancer	0.00118	0.0179	CbGeAlD
Isoprenaline—Nervousness—Estrone—prostate cancer	0.000868	0.00947	CcSEcCtD
Isoprenaline—Angina pectoris—Bicalutamide—prostate cancer	0.000838	0.00914	CcSEcCtD
Isoprenaline—Tension—Nilutamide—prostate cancer	0.000815	0.00888	CcSEcCtD
Isoprenaline—Tension—Flutamide—prostate cancer	0.000811	0.00884	CcSEcCtD
Isoprenaline—Nervousness—Nilutamide—prostate cancer	0.000806	0.00879	CcSEcCtD
Isoprenaline—Nervousness—Flutamide—prostate cancer	0.000803	0.00875	CcSEcCtD
Isoprenaline—Hypertension—Abiraterone—prostate cancer	0.000785	0.00856	CcSEcCtD
Isoprenaline—Tension—Estradiol valerate/Dienogest—prostate cancer	0.000766	0.00835	CcSEcCtD
Isoprenaline—Arrhythmia—Degarelix—prostate cancer	0.000761	0.0083	CcSEcCtD
Isoprenaline—Nervousness—Estradiol valerate/Dienogest—prostate cancer	0.000758	0.00826	CcSEcCtD
Isoprenaline—Flushing—Cabazitaxel—prostate cancer	0.000745	0.00812	CcSEcCtD
Isoprenaline—CYP1A1—epithelium—prostate cancer	0.000742	0.0113	CbGeAlD
Isoprenaline—Sweating—Bicalutamide—prostate cancer	0.000735	0.00802	CcSEcCtD
Isoprenaline—Masoprocol—IGF1R—prostate cancer	0.000718	0.125	CrCbGaD
Isoprenaline—Arrhythmia—Cabazitaxel—prostate cancer	0.000717	0.00782	CcSEcCtD
Isoprenaline—Hypertension—Nilutamide—prostate cancer	0.000717	0.00782	CcSEcCtD
Isoprenaline—Hypertension—Flutamide—prostate cancer	0.000714	0.00778	CcSEcCtD
Isoprenaline—Vision blurred—Degarelix—prostate cancer	0.000699	0.00762	CcSEcCtD
Isoprenaline—Insomnia—Estramustine—prostate cancer	0.000691	0.00753	CcSEcCtD
Isoprenaline—Palpitations—Estradiol valerate/Dienogest—prostate cancer	0.000689	0.00752	CcSEcCtD
Isoprenaline—CYP1A1—renal system—prostate cancer	0.000688	0.0104	CbGeAlD
Isoprenaline—Dyspnoea—Estramustine—prostate cancer	0.000681	0.00742	CcSEcCtD
Isoprenaline—CYP1A1—urethra—prostate cancer	0.000676	0.0103	CbGeAlD
Isoprenaline—Insomnia—Abiraterone—prostate cancer	0.000671	0.00732	CcSEcCtD
Isoprenaline—Dyspnoea—Abiraterone—prostate cancer	0.000661	0.00721	CcSEcCtD
Isoprenaline—Palpitations—Degarelix—prostate cancer	0.000656	0.00715	CcSEcCtD
Isoprenaline—Hyperhidrosis—Nilutamide—prostate cancer	0.000655	0.00714	CcSEcCtD
Isoprenaline—Hypertension—Degarelix—prostate cancer	0.00064	0.00698	CcSEcCtD
Isoprenaline—Vertigo—Cabazitaxel—prostate cancer	0.000628	0.00685	CcSEcCtD
Isoprenaline—Arrhythmia—Bicalutamide—prostate cancer	0.000615	0.00671	CcSEcCtD
Isoprenaline—Insomnia—Nilutamide—prostate cancer	0.000613	0.00668	CcSEcCtD
Isoprenaline—Insomnia—Flutamide—prostate cancer	0.00061	0.00665	CcSEcCtD
Isoprenaline—Dyspnoea—Nilutamide—prostate cancer	0.000604	0.00659	CcSEcCtD
Isoprenaline—Hypertension—Cabazitaxel—prostate cancer	0.000603	0.00658	CcSEcCtD
Isoprenaline—Tension—Bicalutamide—prostate cancer	0.000588	0.00641	CcSEcCtD
Isoprenaline—Hyperhidrosis—Degarelix—prostate cancer	0.000585	0.00638	CcSEcCtD
Isoprenaline—Bronchospasm—Conjugated Estrogens—prostate cancer	0.000583	0.00636	CcSEcCtD
Isoprenaline—Angina pectoris—Goserelin—prostate cancer	0.000583	0.00636	CcSEcCtD
Isoprenaline—Nervousness—Bicalutamide—prostate cancer	0.000582	0.00635	CcSEcCtD
Isoprenaline—Hypotension—Degarelix—prostate cancer	0.000566	0.00617	CcSEcCtD
Isoprenaline—Tachycardia—Cabazitaxel—prostate cancer	0.000557	0.00607	CcSEcCtD
Isoprenaline—Insomnia—Degarelix—prostate cancer	0.000548	0.00597	CcSEcCtD
Isoprenaline—Dyspnoea—Degarelix—prostate cancer	0.00054	0.00588	CcSEcCtD
Isoprenaline—Hypotension—Cabazitaxel—prostate cancer	0.000533	0.00581	CcSEcCtD
Isoprenaline—Asthenia—Abiraterone—prostate cancer	0.000532	0.0058	CcSEcCtD
Isoprenaline—Hypertension—Bicalutamide—prostate cancer	0.000518	0.00564	CcSEcCtD
Isoprenaline—Sweating—Goserelin—prostate cancer	0.000512	0.00558	CcSEcCtD
Isoprenaline—Dyspnoea—Cabazitaxel—prostate cancer	0.000508	0.00554	CcSEcCtD
Isoprenaline—Asthenia—Nilutamide—prostate cancer	0.000486	0.0053	CcSEcCtD
Isoprenaline—Asthenia—Flutamide—prostate cancer	0.000484	0.00528	CcSEcCtD
Isoprenaline—Dizziness—Estrone—prostate cancer	0.000482	0.00526	CcSEcCtD
Isoprenaline—Headache—Estramustine—prostate cancer	0.000478	0.00522	CcSEcCtD
Isoprenaline—Hyperhidrosis—Bicalutamide—prostate cancer	0.000473	0.00516	CcSEcCtD
Isoprenaline—Bronchospasm—Estradiol—prostate cancer	0.000467	0.00509	CcSEcCtD
Isoprenaline—Headache—Estrone—prostate cancer	0.000457	0.00498	CcSEcCtD
Isoprenaline—Asthenia—Estradiol valerate/Dienogest—prostate cancer	0.000457	0.00498	CcSEcCtD
Isoprenaline—Nausea—Estramustine—prostate cancer	0.000454	0.00495	CcSEcCtD
Isoprenaline—Dizziness—Nilutamide—prostate cancer	0.000448	0.00489	CcSEcCtD
Isoprenaline—Dizziness—Flutamide—prostate cancer	0.000446	0.00486	CcSEcCtD
Isoprenaline—Ventricular arrhythmia—Epirubicin—prostate cancer	0.000444	0.00484	CcSEcCtD
Isoprenaline—Insomnia—Bicalutamide—prostate cancer	0.000442	0.00482	CcSEcCtD
Isoprenaline—Dyspnoea—Bicalutamide—prostate cancer	0.000436	0.00476	CcSEcCtD
Isoprenaline—Asthenia—Degarelix—prostate cancer	0.000434	0.00474	CcSEcCtD
Isoprenaline—Pulmonary oedema—Docetaxel—prostate cancer	0.000434	0.00473	CcSEcCtD
Isoprenaline—Nausea—Estrone—prostate cancer	0.000433	0.00473	CcSEcCtD
Isoprenaline—Arrhythmia—Goserelin—prostate cancer	0.000428	0.00467	CcSEcCtD
Isoprenaline—Headache—Nilutamide—prostate cancer	0.000425	0.00463	CcSEcCtD
Isoprenaline—Arrhythmia—Conjugated Estrogens—prostate cancer	0.000424	0.00462	CcSEcCtD
Isoprenaline—Headache—Flutamide—prostate cancer	0.000423	0.00461	CcSEcCtD
Isoprenaline—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.000421	0.00459	CcSEcCtD
Isoprenaline—Ventricular arrhythmia—Doxorubicin—prostate cancer	0.000411	0.00448	CcSEcCtD
Isoprenaline—Tension—Goserelin—prostate cancer	0.000409	0.00446	CcSEcCtD
Isoprenaline—Asthenia—Cabazitaxel—prostate cancer	0.000409	0.00446	CcSEcCtD
Isoprenaline—Tension—Conjugated Estrogens—prostate cancer	0.000405	0.00442	CcSEcCtD
Isoprenaline—Nervousness—Goserelin—prostate cancer	0.000405	0.00442	CcSEcCtD
Isoprenaline—Cardiac arrest—Etoposide—prostate cancer	0.000405	0.00441	CcSEcCtD
Isoprenaline—Nausea—Nilutamide—prostate cancer	0.000403	0.00439	CcSEcCtD
Isoprenaline—Nervousness—Conjugated Estrogens—prostate cancer	0.000401	0.00437	CcSEcCtD
Isoprenaline—Nausea—Flutamide—prostate cancer	0.000401	0.00437	CcSEcCtD
Isoprenaline—Dizziness—Degarelix—prostate cancer	0.0004	0.00436	CcSEcCtD
Isoprenaline—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000399	0.00435	CcSEcCtD
Isoprenaline—Vision blurred—Goserelin—prostate cancer	0.000393	0.00428	CcSEcCtD
Isoprenaline—Vision blurred—Conjugated Estrogens—prostate cancer	0.000389	0.00424	CcSEcCtD
Isoprenaline—Headache—Degarelix—prostate cancer	0.000379	0.00414	CcSEcCtD
Isoprenaline—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000378	0.00412	CcSEcCtD
Isoprenaline—Sweating—Mitoxantrone—prostate cancer	0.000378	0.00412	CcSEcCtD
Isoprenaline—Dizziness—Cabazitaxel—prostate cancer	0.000377	0.00411	CcSEcCtD
Isoprenaline—Pulmonary oedema—Prednisone—prostate cancer	0.000374	0.00408	CcSEcCtD
Isoprenaline—Orciprenaline—ADRB2—prostate cancer	0.000371	0.0649	CrCbGaD
Isoprenaline—Vertigo—Conjugated Estrogens—prostate cancer	0.000371	0.00405	CcSEcCtD
Isoprenaline—Palpitations—Goserelin—prostate cancer	0.000369	0.00402	CcSEcCtD
Isoprenaline—Palpitations—Conjugated Estrogens—prostate cancer	0.000365	0.00398	CcSEcCtD
Isoprenaline—Bronchospasm—Etoposide—prostate cancer	0.000362	0.00394	CcSEcCtD
Isoprenaline—Convulsion—Goserelin—prostate cancer	0.000361	0.00394	CcSEcCtD
Isoprenaline—Hypertension—Goserelin—prostate cancer	0.00036	0.00393	CcSEcCtD
Isoprenaline—Nausea—Degarelix—prostate cancer	0.00036	0.00392	CcSEcCtD
Isoprenaline—Convulsion—Conjugated Estrogens—prostate cancer	0.000358	0.0039	CcSEcCtD
Isoprenaline—Headache—Cabazitaxel—prostate cancer	0.000357	0.0039	CcSEcCtD
Isoprenaline—Flushing—Estradiol—prostate cancer	0.000352	0.00384	CcSEcCtD
Isoprenaline—Asthenia—Bicalutamide—prostate cancer	0.000351	0.00383	CcSEcCtD
Isoprenaline—Nausea—Cabazitaxel—prostate cancer	0.000339	0.00369	CcSEcCtD
Isoprenaline—Tachycardia—Goserelin—prostate cancer	0.000332	0.00362	CcSEcCtD
Isoprenaline—Hyperhidrosis—Goserelin—prostate cancer	0.000329	0.00359	CcSEcCtD
Isoprenaline—Tachycardia—Conjugated Estrogens—prostate cancer	0.000329	0.00359	CcSEcCtD
Isoprenaline—Hyperhidrosis—Conjugated Estrogens—prostate cancer	0.000326	0.00355	CcSEcCtD
Isoprenaline—Cardiac arrest—Capecitabine—prostate cancer	0.000326	0.00355	CcSEcCtD
Isoprenaline—Tension—Estradiol—prostate cancer	0.000324	0.00354	CcSEcCtD
Isoprenaline—Dizziness—Bicalutamide—prostate cancer	0.000324	0.00353	CcSEcCtD
Isoprenaline—CYP1A1—lymph node—prostate cancer	0.000322	0.00489	CbGeAlD
Isoprenaline—Nervousness—Estradiol—prostate cancer	0.000321	0.0035	CcSEcCtD
Isoprenaline—Methyldopa—COMT—prostate cancer	0.000321	0.0561	CrCbGaD
Isoprenaline—Hypotension—Goserelin—prostate cancer	0.000318	0.00347	CcSEcCtD
Isoprenaline—Arrhythmia—Mitoxantrone—prostate cancer	0.000316	0.00345	CcSEcCtD
Isoprenaline—Hypotension—Conjugated Estrogens—prostate cancer	0.000315	0.00343	CcSEcCtD
Isoprenaline—Tremor—Estradiol—prostate cancer	0.00031	0.00338	CcSEcCtD
Isoprenaline—Insomnia—Goserelin—prostate cancer	0.000308	0.00336	CcSEcCtD
Isoprenaline—Headache—Bicalutamide—prostate cancer	0.000306	0.00334	CcSEcCtD
Isoprenaline—Insomnia—Conjugated Estrogens—prostate cancer	0.000305	0.00332	CcSEcCtD
Isoprenaline—Dyspnoea—Goserelin—prostate cancer	0.000303	0.00331	CcSEcCtD
Isoprenaline—Bronchospasm—Docetaxel—prostate cancer	0.000301	0.00328	CcSEcCtD
Isoprenaline—Dyspnoea—Conjugated Estrogens—prostate cancer	0.000301	0.00328	CcSEcCtD
Isoprenaline—Angina pectoris—Docetaxel—prostate cancer	0.000298	0.00325	CcSEcCtD
Isoprenaline—Vertigo—Estradiol—prostate cancer	0.000297	0.00324	CcSEcCtD
Isoprenaline—Asthenia—Ethinyl Estradiol—prostate cancer	0.000297	0.00323	CcSEcCtD
Isoprenaline—Pulmonary oedema—Epirubicin—prostate cancer	0.000292	0.00319	CcSEcCtD
Isoprenaline—Palpitations—Estradiol—prostate cancer	0.000292	0.00319	CcSEcCtD
Isoprenaline—Bronchospasm—Capecitabine—prostate cancer	0.000291	0.00317	CcSEcCtD
Isoprenaline—Nausea—Bicalutamide—prostate cancer	0.000291	0.00317	CcSEcCtD
Isoprenaline—Vision blurred—Mitoxantrone—prostate cancer	0.00029	0.00317	CcSEcCtD
Isoprenaline—Cardiac arrest—Prednisone—prostate cancer	0.00029	0.00316	CcSEcCtD
Isoprenaline—Angina pectoris—Capecitabine—prostate cancer	0.000288	0.00314	CcSEcCtD
Isoprenaline—Hypertension—Estradiol—prostate cancer	0.000285	0.00311	CcSEcCtD
Isoprenaline—Dizziness—Ethinyl Estradiol—prostate cancer	0.000273	0.00298	CcSEcCtD
Isoprenaline—Flushing—Etoposide—prostate cancer	0.000273	0.00298	CcSEcCtD
Isoprenaline—Pulmonary oedema—Doxorubicin—prostate cancer	0.000271	0.00295	CcSEcCtD
Isoprenaline—Convulsion—Mitoxantrone—prostate cancer	0.000267	0.00291	CcSEcCtD
Isoprenaline—Hypertension—Mitoxantrone—prostate cancer	0.000266	0.0029	CcSEcCtD
Isoprenaline—Tachycardia—Estradiol—prostate cancer	0.000263	0.00287	CcSEcCtD
Isoprenaline—Hyperhidrosis—Estradiol—prostate cancer	0.000261	0.00284	CcSEcCtD
Isoprenaline—Headache—Ethinyl Estradiol—prostate cancer	0.000259	0.00282	CcSEcCtD
Isoprenaline—Nausea—Ethinyl Estradiol—prostate cancer	0.000246	0.00268	CcSEcCtD
Isoprenaline—Tachycardia—Mitoxantrone—prostate cancer	0.000245	0.00268	CcSEcCtD
Isoprenaline—Asthenia—Goserelin—prostate cancer	0.000244	0.00266	CcSEcCtD
Isoprenaline—Insomnia—Estradiol—prostate cancer	0.000244	0.00266	CcSEcCtD
Isoprenaline—Terbutaline—ADRB2—prostate cancer	0.000244	0.0426	CrCbGaD
Isoprenaline—Hyperhidrosis—Mitoxantrone—prostate cancer	0.000243	0.00265	CcSEcCtD
Isoprenaline—Asthenia—Conjugated Estrogens—prostate cancer	0.000242	0.00264	CcSEcCtD
Isoprenaline—Dyspnoea—Estradiol—prostate cancer	0.000241	0.00262	CcSEcCtD
Isoprenaline—Hypotension—Mitoxantrone—prostate cancer	0.000235	0.00256	CcSEcCtD
Isoprenaline—Isoetarine—ADRB2—prostate cancer	0.000235	0.041	CrCbGaD
Isoprenaline—Vertigo—Etoposide—prostate cancer	0.00023	0.00251	CcSEcCtD
Isoprenaline—Masoprocol—CYP19A1—prostate cancer	0.000227	0.0397	CrCbGaD
Isoprenaline—Flushing—Docetaxel—prostate cancer	0.000227	0.00248	CcSEcCtD
Isoprenaline—Cardiac arrest—Epirubicin—prostate cancer	0.000227	0.00247	CcSEcCtD
Isoprenaline—Sotalol—ADRB2—prostate cancer	0.000227	0.0396	CrCbGaD
Isoprenaline—Dizziness—Goserelin—prostate cancer	0.000225	0.00245	CcSEcCtD
Isoprenaline—Dyspnoea—Mitoxantrone—prostate cancer	0.000224	0.00244	CcSEcCtD
Isoprenaline—Dizziness—Conjugated Estrogens—prostate cancer	0.000223	0.00243	CcSEcCtD
Isoprenaline—Convulsion—Etoposide—prostate cancer	0.000222	0.00242	CcSEcCtD
Isoprenaline—Arformoterol—CYP2A6—prostate cancer	0.000222	0.0388	CrCbGaD
Isoprenaline—Formoterol—CYP2A6—prostate cancer	0.000222	0.0388	CrCbGaD
Isoprenaline—Hypertension—Etoposide—prostate cancer	0.000221	0.00241	CcSEcCtD
Isoprenaline—Flushing—Capecitabine—prostate cancer	0.00022	0.0024	CcSEcCtD
Isoprenaline—Arrhythmia—Docetaxel—prostate cancer	0.000219	0.00238	CcSEcCtD
Isoprenaline—Headache—Goserelin—prostate cancer	0.000213	0.00232	CcSEcCtD
Isoprenaline—Arrhythmia—Capecitabine—prostate cancer	0.000212	0.00231	CcSEcCtD
Isoprenaline—Headache—Conjugated Estrogens—prostate cancer	0.000211	0.0023	CcSEcCtD
Isoprenaline—Cardiac arrest—Doxorubicin—prostate cancer	0.00021	0.00229	CcSEcCtD
Isoprenaline—Tachycardia—Etoposide—prostate cancer	0.000204	0.00223	CcSEcCtD
Isoprenaline—Nausea—Goserelin—prostate cancer	0.000202	0.0022	CcSEcCtD
Isoprenaline—Hyperhidrosis—Etoposide—prostate cancer	0.000202	0.0022	CcSEcCtD
Isoprenaline—Angina pectoris—Epirubicin—prostate cancer	0.000201	0.00219	CcSEcCtD
Isoprenaline—Nausea—Conjugated Estrogens—prostate cancer	0.0002	0.00218	CcSEcCtD
Isoprenaline—Fenoterol—ADRB2—prostate cancer	0.0002	0.0349	CrCbGaD
Isoprenaline—Norepinephrine—SLC22A3—prostate cancer	0.000197	0.0345	CrCbGaD
Isoprenaline—Flushing—Prednisone—prostate cancer	0.000196	0.00213	CcSEcCtD
Isoprenaline—Hypotension—Etoposide—prostate cancer	0.000195	0.00213	CcSEcCtD
Isoprenaline—Vision blurred—Capecitabine—prostate cancer	0.000194	0.00212	CcSEcCtD
Isoprenaline—Asthenia—Estradiol—prostate cancer	0.000194	0.00211	CcSEcCtD
Isoprenaline—Tremor—Capecitabine—prostate cancer	0.000193	0.00211	CcSEcCtD
Isoprenaline—Arrhythmia—Prednisone—prostate cancer	0.000188	0.00205	CcSEcCtD
Isoprenaline—Palpitations—Docetaxel—prostate cancer	0.000188	0.00205	CcSEcCtD
Isoprenaline—Arbutamine—ADRB2—prostate cancer	0.000187	0.0326	CrCbGaD
Isoprenaline—Dyspnoea—Etoposide—prostate cancer	0.000186	0.00203	CcSEcCtD
Isoprenaline—Angina pectoris—Doxorubicin—prostate cancer	0.000186	0.00203	CcSEcCtD
Isoprenaline—Vertigo—Capecitabine—prostate cancer	0.000185	0.00202	CcSEcCtD
Isoprenaline—Convulsion—Docetaxel—prostate cancer	0.000184	0.00201	CcSEcCtD
Isoprenaline—Hypertension—Docetaxel—prostate cancer	0.000184	0.002	CcSEcCtD
Isoprenaline—Dopamine—SLC22A3—prostate cancer	0.000183	0.0321	CrCbGaD
Isoprenaline—Palpitations—Capecitabine—prostate cancer	0.000182	0.00199	CcSEcCtD
Isoprenaline—Formoterol—ADRB2—prostate cancer	0.000181	0.0317	CrCbGaD
Isoprenaline—Arformoterol—ADRB2—prostate cancer	0.000181	0.0317	CrCbGaD
Isoprenaline—Salbutamol—ADRB2—prostate cancer	0.000181	0.0317	CrCbGaD
Isoprenaline—Asthenia—Mitoxantrone—prostate cancer	0.00018	0.00197	CcSEcCtD
Isoprenaline—Dizziness—Estradiol—prostate cancer	0.000178	0.00195	CcSEcCtD
Isoprenaline—Hypertension—Capecitabine—prostate cancer	0.000178	0.00194	CcSEcCtD
Isoprenaline—Sweating—Epirubicin—prostate cancer	0.000176	0.00192	CcSEcCtD
Isoprenaline—Vision blurred—Prednisone—prostate cancer	0.000173	0.00189	CcSEcCtD
Isoprenaline—Tachycardia—Docetaxel—prostate cancer	0.00017	0.00185	CcSEcCtD
Isoprenaline—Headache—Estradiol—prostate cancer	0.000169	0.00184	CcSEcCtD
Isoprenaline—Vertigo—Prednisone—prostate cancer	0.000165	0.0018	CcSEcCtD
Isoprenaline—Tachycardia—Capecitabine—prostate cancer	0.000164	0.00179	CcSEcCtD
Isoprenaline—Sweating—Doxorubicin—prostate cancer	0.000163	0.00178	CcSEcCtD
Isoprenaline—Hyperhidrosis—Capecitabine—prostate cancer	0.000163	0.00177	CcSEcCtD
Isoprenaline—Hypotension—Docetaxel—prostate cancer	0.000162	0.00177	CcSEcCtD
Isoprenaline—Nausea—Estradiol—prostate cancer	0.00016	0.00175	CcSEcCtD
Isoprenaline—Convulsion—Prednisone—prostate cancer	0.000159	0.00173	CcSEcCtD
Isoprenaline—Hypertension—Prednisone—prostate cancer	0.000159	0.00173	CcSEcCtD
Isoprenaline—Headache—Mitoxantrone—prostate cancer	0.000157	0.00172	CcSEcCtD
Isoprenaline—Hypotension—Capecitabine—prostate cancer	0.000157	0.00171	CcSEcCtD
Isoprenaline—Insomnia—Docetaxel—prostate cancer	0.000157	0.00171	CcSEcCtD
Isoprenaline—Dopamine—COMT—prostate cancer	0.000157	0.0274	CrCbGaD
Isoprenaline—Arformoterol—CYP2C19—prostate cancer	0.000156	0.0273	CrCbGaD
Isoprenaline—Formoterol—CYP2C19—prostate cancer	0.000156	0.0273	CrCbGaD
Isoprenaline—Dyspnoea—Docetaxel—prostate cancer	0.000155	0.00169	CcSEcCtD
Isoprenaline—Flushing—Epirubicin—prostate cancer	0.000153	0.00167	CcSEcCtD
Isoprenaline—Insomnia—Capecitabine—prostate cancer	0.000152	0.00166	CcSEcCtD
Isoprenaline—Asthenia—Etoposide—prostate cancer	0.00015	0.00164	CcSEcCtD
Isoprenaline—Dyspnoea—Capecitabine—prostate cancer	0.00015	0.00164	CcSEcCtD
Isoprenaline—Nausea—Mitoxantrone—prostate cancer	0.000149	0.00163	CcSEcCtD
Isoprenaline—Arrhythmia—Epirubicin—prostate cancer	0.000147	0.00161	CcSEcCtD
Isoprenaline—Tachycardia—Prednisone—prostate cancer	0.000146	0.00159	CcSEcCtD
Isoprenaline—Hyperhidrosis—Prednisone—prostate cancer	0.000145	0.00158	CcSEcCtD
Isoprenaline—Flushing—Doxorubicin—prostate cancer	0.000142	0.00154	CcSEcCtD
Isoprenaline—Norepinephrine—SLC22A1—prostate cancer	0.000141	0.0247	CrCbGaD
Isoprenaline—Tension—Epirubicin—prostate cancer	0.000141	0.00154	CcSEcCtD
Isoprenaline—Nervousness—Epirubicin—prostate cancer	0.000139	0.00152	CcSEcCtD
Isoprenaline—Dizziness—Etoposide—prostate cancer	0.000138	0.00151	CcSEcCtD
Isoprenaline—Arrhythmia—Doxorubicin—prostate cancer	0.000136	0.00149	CcSEcCtD
Isoprenaline—Insomnia—Prednisone—prostate cancer	0.000136	0.00148	CcSEcCtD
Isoprenaline—Vision blurred—Epirubicin—prostate cancer	0.000135	0.00148	CcSEcCtD
Isoprenaline—Labetalol—ADRB2—prostate cancer	0.000132	0.0232	CrCbGaD
Isoprenaline—Dopamine—SLC22A1—prostate cancer	0.000132	0.023	CrCbGaD
Isoprenaline—Headache—Etoposide—prostate cancer	0.000131	0.00143	CcSEcCtD
Isoprenaline—Tension—Doxorubicin—prostate cancer	0.00013	0.00142	CcSEcCtD
Isoprenaline—Nervousness—Doxorubicin—prostate cancer	0.000129	0.00141	CcSEcCtD
Isoprenaline—Vertigo—Epirubicin—prostate cancer	0.000129	0.00141	CcSEcCtD
Isoprenaline—Epinephrine—SLC22A1—prostate cancer	0.000128	0.0224	CrCbGaD
Isoprenaline—Pindolol—ADRB2—prostate cancer	0.000127	0.0222	CrCbGaD
Isoprenaline—Palpitations—Epirubicin—prostate cancer	0.000127	0.00138	CcSEcCtD
Isoprenaline—Vision blurred—Doxorubicin—prostate cancer	0.000125	0.00137	CcSEcCtD
Isoprenaline—Asthenia—Docetaxel—prostate cancer	0.000125	0.00136	CcSEcCtD
Isoprenaline—Convulsion—Epirubicin—prostate cancer	0.000124	0.00136	CcSEcCtD
Isoprenaline—Nausea—Etoposide—prostate cancer	0.000124	0.00135	CcSEcCtD
Isoprenaline—Hypertension—Epirubicin—prostate cancer	0.000124	0.00135	CcSEcCtD
Isoprenaline—Asthenia—Capecitabine—prostate cancer	0.000121	0.00132	CcSEcCtD
Isoprenaline—Vertigo—Doxorubicin—prostate cancer	0.000119	0.0013	CcSEcCtD
Isoprenaline—Palpitations—Doxorubicin—prostate cancer	0.000117	0.00128	CcSEcCtD
Isoprenaline—Convulsion—Doxorubicin—prostate cancer	0.000115	0.00126	CcSEcCtD
Isoprenaline—Dizziness—Docetaxel—prostate cancer	0.000115	0.00125	CcSEcCtD
Isoprenaline—Hypertension—Doxorubicin—prostate cancer	0.000115	0.00125	CcSEcCtD
Isoprenaline—Tachycardia—Epirubicin—prostate cancer	0.000114	0.00125	CcSEcCtD
Isoprenaline—Hyperhidrosis—Epirubicin—prostate cancer	0.000113	0.00124	CcSEcCtD
Isoprenaline—Dizziness—Capecitabine—prostate cancer	0.000111	0.00121	CcSEcCtD
Isoprenaline—Hypotension—Epirubicin—prostate cancer	0.00011	0.00119	CcSEcCtD
Isoprenaline—Headache—Docetaxel—prostate cancer	0.000109	0.00119	CcSEcCtD
Isoprenaline—Asthenia—Prednisone—prostate cancer	0.000108	0.00117	CcSEcCtD
Isoprenaline—Droxidopa—ADRB2—prostate cancer	0.000107	0.0187	CrCbGaD
Isoprenaline—Insomnia—Epirubicin—prostate cancer	0.000106	0.00116	CcSEcCtD
Isoprenaline—Tachycardia—Doxorubicin—prostate cancer	0.000106	0.00115	CcSEcCtD
Isoprenaline—Headache—Capecitabine—prostate cancer	0.000105	0.00115	CcSEcCtD
Isoprenaline—Hyperhidrosis—Doxorubicin—prostate cancer	0.000105	0.00114	CcSEcCtD
Isoprenaline—Dyspnoea—Epirubicin—prostate cancer	0.000104	0.00114	CcSEcCtD
Isoprenaline—Nausea—Docetaxel—prostate cancer	0.000103	0.00113	CcSEcCtD
Isoprenaline—Hypotension—Doxorubicin—prostate cancer	0.000101	0.0011	CcSEcCtD
Isoprenaline—Nausea—Capecitabine—prostate cancer	9.99e-05	0.00109	CcSEcCtD
Isoprenaline—Salbutamol—CYP3A4—prostate cancer	9.92e-05	0.0173	CrCbGaD
Isoprenaline—Dizziness—Prednisone—prostate cancer	9.91e-05	0.00108	CcSEcCtD
Isoprenaline—Insomnia—Doxorubicin—prostate cancer	9.81e-05	0.00107	CcSEcCtD
Isoprenaline—Dyspnoea—Doxorubicin—prostate cancer	9.67e-05	0.00105	CcSEcCtD
Isoprenaline—Headache—Prednisone—prostate cancer	9.39e-05	0.00102	CcSEcCtD
Isoprenaline—Norepinephrine—ADRB2—prostate cancer	9.03e-05	0.0158	CrCbGaD
Isoprenaline—Nausea—Prednisone—prostate cancer	8.9e-05	0.000971	CcSEcCtD
Isoprenaline—Asthenia—Epirubicin—prostate cancer	8.41e-05	0.000917	CcSEcCtD
Isoprenaline—Epinephrine—ADRB2—prostate cancer	8.19e-05	0.0143	CrCbGaD
Isoprenaline—Asthenia—Doxorubicin—prostate cancer	7.78e-05	0.000848	CcSEcCtD
Isoprenaline—Dizziness—Epirubicin—prostate cancer	7.75e-05	0.000845	CcSEcCtD
Isoprenaline—Headache—Epirubicin—prostate cancer	7.34e-05	0.000801	CcSEcCtD
Isoprenaline—Dopamine—CYP2C19—prostate cancer	7.22e-05	0.0126	CrCbGaD
Isoprenaline—Dizziness—Doxorubicin—prostate cancer	7.17e-05	0.000782	CcSEcCtD
Isoprenaline—Nausea—Epirubicin—prostate cancer	6.96e-05	0.000759	CcSEcCtD
Isoprenaline—Headache—Doxorubicin—prostate cancer	6.79e-05	0.000741	CcSEcCtD
Isoprenaline—Nausea—Doxorubicin—prostate cancer	6.44e-05	0.000702	CcSEcCtD
Isoprenaline—Epinephrine—CYP3A4—prostate cancer	4.48e-05	0.00784	CrCbGaD
Isoprenaline—ADRB2—Signaling by GPCR—IL2—prostate cancer	1.67e-06	6.28e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TERT—prostate cancer	1.66e-06	6.26e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—AKT1—prostate cancer	1.66e-06	6.26e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—EGF—prostate cancer	1.66e-06	6.25e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IRS1—prostate cancer	1.66e-06	6.25e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.66e-06	6.24e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CCND1—prostate cancer	1.66e-06	6.23e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—MYC—prostate cancer	1.65e-06	6.23e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—TGFB1—prostate cancer	1.65e-06	6.21e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—PIK3CA—prostate cancer	1.65e-06	6.21e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—MMP9—prostate cancer	1.65e-06	6.2e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—EGFR—prostate cancer	1.64e-06	6.18e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—COMT—prostate cancer	1.64e-06	6.18e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—EP300—prostate cancer	1.64e-06	6.18e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CDKN1A—prostate cancer	1.64e-06	6.18e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CTNNB1—prostate cancer	1.64e-06	6.17e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—AKT1—prostate cancer	1.64e-06	6.17e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—PTEN—prostate cancer	1.64e-06	6.16e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—GSTP1—prostate cancer	1.63e-06	6.15e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—CTNNB1—prostate cancer	1.63e-06	6.14e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—HIF1A—prostate cancer	1.63e-06	6.12e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—EGFR—prostate cancer	1.62e-06	6.09e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—GSK3B—prostate cancer	1.61e-06	6.07e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—ITPR1—prostate cancer	1.61e-06	6.05e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MMP9—prostate cancer	1.61e-06	6.05e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CDKN1A—prostate cancer	1.6e-06	6.03e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—PTEN—prostate cancer	1.6e-06	6.01e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—AKT1—prostate cancer	1.6e-06	6.01e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—SRC—prostate cancer	1.6e-06	6.01e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—CDKN1A—prostate cancer	1.59e-06	5.99e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—INS—prostate cancer	1.59e-06	5.99e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—HIF1A—prostate cancer	1.59e-06	5.99e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—PTEN—prostate cancer	1.59e-06	5.98e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—LEP—prostate cancer	1.59e-06	5.97e-06	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—IL6—prostate cancer	1.58e-06	5.96e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—IL6—prostate cancer	1.58e-06	5.95e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.58e-06	5.95e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CAV1—prostate cancer	1.57e-06	5.92e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—EP300—prostate cancer	1.56e-06	5.88e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—AKT1—prostate cancer	1.56e-06	5.87e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CREBBP—prostate cancer	1.56e-06	5.87e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KDR—prostate cancer	1.56e-06	5.85e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—LEP—prostate cancer	1.55e-06	5.84e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—KRAS—prostate cancer	1.55e-06	5.84e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—STAT3—prostate cancer	1.54e-06	5.79e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IGF1—prostate cancer	1.54e-06	5.79e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CAV1—prostate cancer	1.54e-06	5.79e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—EGFR—prostate cancer	1.53e-06	5.76e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—KRAS—prostate cancer	1.53e-06	5.75e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—EP300—prostate cancer	1.52e-06	5.74e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KDR—prostate cancer	1.52e-06	5.73e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—TYMS—prostate cancer	1.52e-06	5.72e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—SRC—prostate cancer	1.52e-06	5.71e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—EP300—prostate cancer	1.52e-06	5.7e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—ESR1—prostate cancer	1.52e-06	5.7e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—GSTM1—prostate cancer	1.5e-06	5.65e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MAP2K1—prostate cancer	1.49e-06	5.6e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—ESR1—prostate cancer	1.48e-06	5.58e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—SRC—prostate cancer	1.48e-06	5.58e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—BAD—prostate cancer	1.48e-06	5.57e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—VEGFA—prostate cancer	1.48e-06	5.57e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CD—prostate cancer	1.48e-06	5.56e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—LPL—prostate cancer	1.47e-06	5.55e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—SRC—prostate cancer	1.47e-06	5.55e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—STAT3—prostate cancer	1.46e-06	5.51e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—SERPINE1—prostate cancer	1.46e-06	5.5e-06	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—AKT1—prostate cancer	1.46e-06	5.5e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—IL6—prostate cancer	1.46e-06	5.5e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—AKT1—prostate cancer	1.46e-06	5.49e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—BAD—prostate cancer	1.45e-06	5.45e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—KRAS—prostate cancer	1.45e-06	5.44e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—VEGFA—prostate cancer	1.44e-06	5.43e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—APC—prostate cancer	1.43e-06	5.39e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	1.43e-06	5.39e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—STAT3—prostate cancer	1.43e-06	5.38e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—PIK3CA—prostate cancer	1.43e-06	5.37e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—STAT3—prostate cancer	1.42e-06	5.35e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IRS1—prostate cancer	1.42e-06	5.33e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—EGF—prostate cancer	1.42e-06	5.33e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—FGF2—prostate cancer	1.42e-06	5.32e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—ERCC2—prostate cancer	1.41e-06	5.31e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—PIK3CA—prostate cancer	1.4e-06	5.28e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	1.4e-06	5.27e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—APC—prostate cancer	1.4e-06	5.27e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—EGFR—prostate cancer	1.4e-06	5.27e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—NOS3—prostate cancer	1.4e-06	5.25e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Metabolism—AKT1—prostate cancer	1.39e-06	5.24e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—EGF—prostate cancer	1.39e-06	5.21e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IRS1—prostate cancer	1.39e-06	5.21e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—PIK3CA—prostate cancer	1.38e-06	5.2e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—TP53—prostate cancer	1.38e-06	5.19e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—GSK3B—prostate cancer	1.38e-06	5.17e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—MYC—prostate cancer	1.36e-06	5.12e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—TP53—prostate cancer	1.36e-06	5.11e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—TGFB1—prostate cancer	1.36e-06	5.11e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—JAK2—prostate cancer	1.36e-06	5.1e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—INS—prostate cancer	1.36e-06	5.1e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—AKT1—prostate cancer	1.35e-06	5.07e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—GSK3B—prostate cancer	1.35e-06	5.06e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—EGFR—prostate cancer	1.33e-06	5.01e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—PIK3CA—prostate cancer	1.33e-06	5e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CREBBP—prostate cancer	1.33e-06	5e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MYC—prostate cancer	1.33e-06	5e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—MTHFR—prostate cancer	1.33e-06	4.99e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—INS—prostate cancer	1.33e-06	4.99e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—TGFB1—prostate cancer	1.33e-06	4.99e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MDM2—prostate cancer	1.32e-06	4.98e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—KRAS—prostate cancer	1.32e-06	4.97e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—MYC—prostate cancer	1.32e-06	4.97e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—TGFB1—prostate cancer	1.32e-06	4.96e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IGF1—prostate cancer	1.31e-06	4.94e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—EGFR—prostate cancer	1.31e-06	4.91e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—ERBB2—prostate cancer	1.31e-06	4.91e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PPARA—prostate cancer	1.3e-06	4.9e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CREBBP—prostate cancer	1.3e-06	4.89e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—EGFR—prostate cancer	1.3e-06	4.89e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—EGFR—prostate cancer	1.29e-06	4.86e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CB—prostate cancer	1.29e-06	4.85e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IGF1—prostate cancer	1.28e-06	4.83e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—EGFR—prostate cancer	1.28e-06	4.8e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	1.27e-06	4.77e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—IL6—prostate cancer	1.26e-06	4.75e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	1.26e-06	4.74e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—KRAS—prostate cancer	1.26e-06	4.73e-06	CbGpPWpGaD
Isoprenaline—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	1.25e-06	4.69e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	1.25e-06	4.69e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—IL6—prostate cancer	1.24e-06	4.68e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	1.24e-06	4.67e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CXCL8—prostate cancer	1.24e-06	4.66e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—KRAS—prostate cancer	1.23e-06	4.64e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	1.23e-06	4.64e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—KRAS—prostate cancer	1.23e-06	4.62e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—CAV1—prostate cancer	1.22e-06	4.61e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—KRAS—prostate cancer	1.22e-06	4.59e-06	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	1.22e-06	4.59e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	1.22e-06	4.59e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—PIK3CA—prostate cancer	1.21e-06	4.57e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CDKN1B—prostate cancer	1.21e-06	4.55e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—KRAS—prostate cancer	1.21e-06	4.54e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—FGF2—prostate cancer	1.21e-06	4.54e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—NOS3—prostate cancer	1.19e-06	4.48e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CASP3—prostate cancer	1.18e-06	4.46e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IL2—prostate cancer	1.18e-06	4.45e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—FGF2—prostate cancer	1.18e-06	4.44e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—IL6—prostate cancer	1.18e-06	4.43e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.17e-06	4.4e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—AKT1—prostate cancer	1.16e-06	4.38e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—NOS3—prostate cancer	1.16e-06	4.38e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—JAK2—prostate cancer	1.16e-06	4.35e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—PIK3CA—prostate cancer	1.16e-06	4.35e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CCND1—prostate cancer	1.15e-06	4.34e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—AKT1—prostate cancer	1.15e-06	4.32e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CTNNB1—prostate cancer	1.14e-06	4.3e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	1.13e-06	4.26e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—JAK2—prostate cancer	1.13e-06	4.25e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—AKT1—prostate cancer	1.13e-06	4.25e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MDM2—prostate cancer	1.13e-06	4.25e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—PIK3CA—prostate cancer	1.13e-06	4.24e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—PIK3CA—prostate cancer	1.12e-06	4.22e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MMP9—prostate cancer	1.12e-06	4.21e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—TP53—prostate cancer	1.12e-06	4.21e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CDKN1A—prostate cancer	1.12e-06	4.2e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CG—prostate cancer	1.12e-06	4.2e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PTEN—prostate cancer	1.11e-06	4.19e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—ERBB2—prostate cancer	1.11e-06	4.19e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	1.11e-06	4.17e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MDM2—prostate cancer	1.1e-06	4.15e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	1.1e-06	4.13e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—TP53—prostate cancer	1.09e-06	4.1e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—ERBB2—prostate cancer	1.09e-06	4.09e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—AKT1—prostate cancer	1.09e-06	4.09e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—IL6—prostate cancer	1.08e-06	4.05e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	1.07e-06	4.04e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—EP300—prostate cancer	1.06e-06	3.99e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—INS—prostate cancer	1.06e-06	3.97e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CXCL8—prostate cancer	1.06e-06	3.97e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—CREBBP—prostate cancer	1.03e-06	3.89e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—SRC—prostate cancer	1.03e-06	3.88e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CXCL8—prostate cancer	1.03e-06	3.88e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	1.03e-06	3.88e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—IL6—prostate cancer	1.02e-06	3.85e-06	CbGpPWpGaD
Isoprenaline—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	1.02e-06	3.83e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CASP3—prostate cancer	1.01e-06	3.8e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IL2—prostate cancer	1.01e-06	3.79e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	1.01e-06	3.79e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—VEGFA—prostate cancer	1.01e-06	3.78e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—IL6—prostate cancer	1e-06	3.77e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—IL6—prostate cancer	9.99e-07	3.76e-06	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	9.97e-07	3.75e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—STAT3—prostate cancer	9.96e-07	3.75e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—IL6—prostate cancer	9.93e-07	3.74e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—AKT1—prostate cancer	9.92e-07	3.73e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CASP3—prostate cancer	9.88e-07	3.72e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IL2—prostate cancer	9.86e-07	3.71e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CCND1—prostate cancer	9.83e-07	3.7e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—IL6—prostate cancer	9.81e-07	3.69e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CD—prostate cancer	9.81e-07	3.69e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	9.73e-07	3.66e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CCND1—prostate cancer	9.62e-07	3.62e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MMP9—prostate cancer	9.54e-07	3.59e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	9.52e-07	3.58e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	9.51e-07	3.58e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PTEN—prostate cancer	9.49e-07	3.57e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—AKT1—prostate cancer	9.44e-07	3.55e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MMP9—prostate cancer	9.34e-07	3.51e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	9.3e-07	3.5e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PTEN—prostate cancer	9.28e-07	3.49e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—NOS3—prostate cancer	9.26e-07	3.48e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—AKT1—prostate cancer	9.26e-07	3.48e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MYC—prostate cancer	9.25e-07	3.48e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—TGFB1—prostate cancer	9.23e-07	3.47e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—AKT1—prostate cancer	9.21e-07	3.47e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—AKT1—prostate cancer	9.16e-07	3.45e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—AKT1—prostate cancer	9.05e-07	3.41e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—EGFR—prostate cancer	9.05e-07	3.4e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—EP300—prostate cancer	9.05e-07	3.4e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—EP300—prostate cancer	8.85e-07	3.33e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—SRC—prostate cancer	8.8e-07	3.31e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—SRC—prostate cancer	8.61e-07	3.24e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—VEGFA—prostate cancer	8.57e-07	3.22e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—KRAS—prostate cancer	8.55e-07	3.22e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CB—prostate cancer	8.55e-07	3.22e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—STAT3—prostate cancer	8.49e-07	3.19e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PTGS2—prostate cancer	8.47e-07	3.19e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—VEGFA—prostate cancer	8.38e-07	3.15e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—STAT3—prostate cancer	8.3e-07	3.12e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MYC—prostate cancer	7.88e-07	2.97e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TGFB1—prostate cancer	7.87e-07	2.96e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CA—prostate cancer	7.85e-07	2.95e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MYC—prostate cancer	7.71e-07	2.9e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—EGFR—prostate cancer	7.71e-07	2.9e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TGFB1—prostate cancer	7.69e-07	2.89e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—TP53—prostate cancer	7.6e-07	2.86e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—EGFR—prostate cancer	7.54e-07	2.84e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PTEN—prostate cancer	7.39e-07	2.78e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KRAS—prostate cancer	7.29e-07	2.74e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KRAS—prostate cancer	7.13e-07	2.68e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—EP300—prostate cancer	7.04e-07	2.65e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IL6—prostate cancer	6.95e-07	2.62e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	6.69e-07	2.52e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	6.55e-07	2.46e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TP53—prostate cancer	6.48e-07	2.44e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—AKT1—prostate cancer	6.42e-07	2.41e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TP53—prostate cancer	6.33e-07	2.38e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IL6—prostate cancer	5.93e-07	2.23e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IL6—prostate cancer	5.8e-07	2.18e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—AKT1—prostate cancer	5.47e-07	2.06e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—AKT1—prostate cancer	5.35e-07	2.01e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CA—prostate cancer	5.21e-07	1.96e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—AKT1—prostate cancer	4.26e-07	1.6e-06	CbGpPWpGaD
